Putney Promotes Dr. Anthony Lucas to Senior VP of Scientific and Medical Affairs - See more at: http://ir.safeguard.com/investor-relations/press-releases/press-release-details/2015/Putney-Promotes-Dr-Anthony-Lucas-to-Senior-VP-of-Scientific-and-Medical-Af

Portland, ME, March 3, 2015 — Putney, Inc., a rapidly growing pet pharmaceutical company focused on the development and sale of generic prescription medicines for pets, has promoted Dr. Anthony Lucas, BVMS, PhD to the newly created position of Senior Vice President of Scientific and Medical Affairs. With this promotion, Dr. Lucas will add to his current responsibilities of overseeing all aspects of pipeline delivery by contributing more broadly to Putney's product launches, leading the technical commercial manufacture and veterinary support teams.

Jean Hoffman, Putney CEO and President, says the promotion recognizes Dr. Lucas' significant contributions in leading the R&D effort that resulted in five FDA product approvals in five months. "As a veterinary scientist with clinical experience and a long career in veterinary pharmaceuticals, Dr. Lucas brings the combination of rigorous science, practical experience and commercial insight to his role at Putney," says Hoffman. Hoffman credits Dr. Lucas' scientific expertise as an instrumental factor in Putney launching four first-to-market generic pet medicines with the same dosage forms as the brand in less than two years, including recently released Putney Carprofen Chewable Tablets (generic of Rimadyl® Chewable Tablets) and Putney Dexmedetomidine HCl (generic of Dexdomitor®).

Dr. Lucas applauds his team's hard work and success and says it is gratifying to develop generic pet medicines that help veterinarians make pet healthcare more affordable for pet owners. "Putney is on an aggressive growth curve. We've assembled a strong R&D team capable of driving multiple products through the pipeline and delivering positive results," says Dr. Lucas. In addition to leading Putney's Scientific and Medical Affairs, Dr. Lucas is current president of the American Academy of Veterinary Pharmacology and Therapeutics and a co-founding member of the board of directors of the Veterinary Pharmacology Research Foundation.

About Putney

Putney is a pharmaceutical company committed to providing high quality, cost-effective generic medicines for pets. Putney's reliable supply of affordable drug options empowers veterinarians, allowing them to provide the best possible medicine at the best possible price, and supports pet owners, helping them afford to comply with veterinary recommendations. Putney's ongoing investment in research and development is focused on creating the next generation of generic veterinary products based on inputs from companion animal veterinarians and its industry partners. Learn more at www.putneyvet.com.

- See more at: http://ir.safeguard.com/investor-relations/press-releases/press-release-details/2015/Putney-Promotes-Dr-Anthony-Lucas-to-Senior-VP-of-Scientific-and-Medical-Affairs/default.aspx#sthash.qs2BlEsf.dpuf

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…